14.50
+0(+0.00%)
Currency In GBp
Address
1100 Melville Street
Vancouver, BC V6E 4A6
Canada
Phone
604-669-0555
Website
Sector
Healthcare
Industry
Biotechnology
Employees
18
First IPO Date
December 06, 2021
| Name | Title | Pay | Year Born |
| Ms. Carolyn M. Cross C.F.A., CFA, M.B.A., MBA | Founder, Chief Executive Officer & Executive Director | 888,928 | N/A |
| Dr. Nicolas G. Loebel Ph.D. | President, Chief Technology Officer & Executive Director | 713,772 | N/A |
| Mr. Alan Thomas | Non-Board Interim Chief Financial Officer | 0 | N/A |
| Mr. Nikita Parkev | Vice President of Finance & Company Secretary | 0 | N/A |
| Mr. William Kanz | Senior Vice President of Engineering & Operations | 0 | N/A |
| Ms. Angelika Vance | Vice President of Corporate Communications | 0 | N/A |
| Mr. Matt Ross | Vice President of Sales & Marketing | 0 | N/A |
Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally. Its product platform is Photodisinfection, a topical light-based antimicrobial technology that eliminates harmful pathogens. The company's lead product is Steriwave, a photodisinfection based medical device that eliminates harmful nasal pathogens, which leads to healthcare-associated infections. Its product pipeline also includes development of a topical antiviral therapy for the upper respiratory tract that reduces SARS-CoV-2 titre and transmission; a solution for treatment of chronic rhinosinusitis; OND1002, a solution for disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia; and OND1003, a solution for decolonization of burns and wounds. The company was incorporated in 1996 and is headquartered in Vancouver, Canada.